The Myeloma Center at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) announced Monday that it is offering  a new cutting-edge immunotherapy treatment for myeloma patients. UAMS is the first and only medical facility in Arkansas approved to provide this type of cellular therapy.Â
Chimeric antigen receptor (CAR) T-cell therapy uses new technology to genetically modify a patient’s own immune cells (T-cells), enabling them to find and destroy cancer cells. The CAR T-cell immunotherapy, also known as ABECMA, arrived at the Myeloma Center this month.
ABECMA, approved by the Federal Drug Administration in late March, collects and genetically modifies the patient’s own T-cells by introducing an antibody fragment that specifically recognizes myeloma cells.Â
The CAR T-cell therapy is presently only approved for myeloma patients who have had multiple relapses or do not respond to any of the standard myeloma drugs.Â
Â
